CA2276063A1 - Secreted proteins and polynucleotides encoding them - Google Patents

Secreted proteins and polynucleotides encoding them Download PDF

Info

Publication number: CA2276063A1
Authority: CA; Canada
Prior art keywords: protein; polynucleotide; amino acid; composition; seq
Prior art date: 1997-01-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002276063A

Other languages

English (en)

French (fr)

Inventor

Kenneth Jacobs

John M. Mccoy

Edward R. Lavallie

Lisa A. Racie

David Merberg

Maurice Treacy

Vikki Spaulding

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Genetics Institute LLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-09

Filing date

1998-01-09

Publication date

1998-07-16

1998-01-09 Application filed by Individual filed Critical Individual

1998-07-16 Publication of CA2276063A1 publication Critical patent/CA2276063A1/en

Status Abandoned legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 320
102000004169 proteins and genes Human genes 0.000 title claims abstract description 312
108091033319 polynucleotide Proteins 0.000 title claims abstract description 104
102000040430 polynucleotide Human genes 0.000 title claims abstract description 104
239000002157 polynucleotide Substances 0.000 title claims abstract description 104
210000004027 cell Anatomy 0.000 claims description 101
239000000203 mixture Substances 0.000 claims description 58
238000000034 method Methods 0.000 claims description 56
239000002773 nucleotide Substances 0.000 claims description 45
125000003729 nucleotide group Chemical group 0.000 claims description 45
125000003275 alpha amino acid group Chemical group 0.000 claims description 38
239000012634 fragment Substances 0.000 claims description 22
150000001413 amino acids Chemical class 0.000 claims description 20
239000002299 complementary DNA Substances 0.000 claims description 18
230000004071 biological effect Effects 0.000 claims description 11
108091026890 Coding region Proteins 0.000 claims description 9
230000008569 process Effects 0.000 claims description 8
239000003937 drug carrier Substances 0.000 claims description 5
210000004962 mammalian cell Anatomy 0.000 claims description 4
239000001963 growth medium Substances 0.000 claims description 3
235000018102 proteins Nutrition 0.000 description 280
230000000694 effects Effects 0.000 description 67
210000001519 tissue Anatomy 0.000 description 40
102000000905 Cadherin Human genes 0.000 description 36
108050007957 Cadherin Proteins 0.000 description 36
210000001744 T-lymphocyte Anatomy 0.000 description 36
238000003556 assay Methods 0.000 description 32
238000011282 treatment Methods 0.000 description 27
206010028980 Neoplasm Diseases 0.000 description 25
239000000427 antigen Substances 0.000 description 25
102000036639 antigens Human genes 0.000 description 25
108091007433 antigens Proteins 0.000 description 25
108090000765 processed proteins & peptides Proteins 0.000 description 24
108020004414 DNA Proteins 0.000 description 22
102000004127 Cytokines Human genes 0.000 description 21
108090000695 Cytokines Proteins 0.000 description 21
239000003446 ligand Substances 0.000 description 20
239000008194 pharmaceutical composition Substances 0.000 description 20
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
230000006870 function Effects 0.000 description 18
102000005962 receptors Human genes 0.000 description 18
108020003175 receptors Proteins 0.000 description 18
239000003795 chemical substances by application Substances 0.000 description 17
210000002435 tendon Anatomy 0.000 description 16
235000001014 amino acid Nutrition 0.000 description 14
210000000988 bone and bone Anatomy 0.000 description 14
201000010099 disease Diseases 0.000 description 13
230000002401 inhibitory effect Effects 0.000 description 13
238000009396 hybridization Methods 0.000 description 12
230000003993 interaction Effects 0.000 description 12
201000011510 cancer Diseases 0.000 description 11
230000012010 growth Effects 0.000 description 11
230000028993 immune response Effects 0.000 description 11
230000035755 proliferation Effects 0.000 description 11
210000003719 b-lymphocyte Anatomy 0.000 description 10
230000000903 blocking effect Effects 0.000 description 10
230000004069 differentiation Effects 0.000 description 10
230000003394 haemopoietic effect Effects 0.000 description 10
210000003041 ligament Anatomy 0.000 description 10
239000000463 material Substances 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
102100026445 A-kinase anchor protein 17A Human genes 0.000 description 9
101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
102000039446 nucleic acids Human genes 0.000 description 9
108020004707 nucleic acids Proteins 0.000 description 9
150000007523 nucleic acids Chemical class 0.000 description 9
239000000523 sample Substances 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
241000282412 Homo Species 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
239000003146 anticoagulant agent Substances 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 8
210000000845 cartilage Anatomy 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
238000005259 measurement Methods 0.000 description 8
230000004936 stimulating effect Effects 0.000 description 8
102000002746 Inhibins Human genes 0.000 description 7
108010004250 Inhibins Proteins 0.000 description 7
241001465754 Metazoa Species 0.000 description 7
240000004808 Saccharomyces cerevisiae Species 0.000 description 7
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
230000003399 chemotactic effect Effects 0.000 description 7
230000007547 defect Effects 0.000 description 7
230000001419 dependent effect Effects 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
230000001900 immune effect Effects 0.000 description 7
230000001939 inductive effect Effects 0.000 description 7
208000015181 infectious disease Diseases 0.000 description 7
239000000893 inhibin Substances 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
238000011160 research Methods 0.000 description 7
210000000130 stem cell Anatomy 0.000 description 7
230000002537 thrombolytic effect Effects 0.000 description 7
239000013598 vector Substances 0.000 description 7
208000023275 Autoimmune disease Diseases 0.000 description 6
206010052428 Wound Diseases 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000003958 hematopoietic stem cell Anatomy 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
230000001737 promoting effect Effects 0.000 description 6
230000017423 tissue regeneration Effects 0.000 description 6
238000002054 transplantation Methods 0.000 description 6
-1 CTLL2 Chemical compound 0.000 description 5
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
208000009329 Graft vs Host Disease Diseases 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
102000043131 MHC class II family Human genes 0.000 description 5
108091054438 MHC class II family Proteins 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
239000000872 buffer Substances 0.000 description 5
238000010367 cloning Methods 0.000 description 5
230000006378 damage Effects 0.000 description 5
230000007812 deficiency Effects 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
239000003814 drug Substances 0.000 description 5
229940028334 follicle stimulating hormone Drugs 0.000 description 5
238000009472 formulation Methods 0.000 description 5
208000024908 graft versus host disease Diseases 0.000 description 5
230000035876 healing Effects 0.000 description 5
230000006698 induction Effects 0.000 description 5
208000014674 injury Diseases 0.000 description 5
239000007788 liquid Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
230000002265 prevention Effects 0.000 description 5
238000000746 purification Methods 0.000 description 5
238000011069 regeneration method Methods 0.000 description 5
230000008439 repair process Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
238000012216 screening Methods 0.000 description 5
239000003352 sequestering agent Substances 0.000 description 5
230000008733 trauma Effects 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
108010059616 Activins Proteins 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
108010074338 Lymphokines Proteins 0.000 description 4
102000008072 Lymphokines Human genes 0.000 description 4
102000043129 MHC class I family Human genes 0.000 description 4
108091054437 MHC class I family Proteins 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
108020005187 Oligonucleotide Probes Proteins 0.000 description 4
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
239000000488 activin Substances 0.000 description 4
230000004075 alteration Effects 0.000 description 4
230000002785 anti-thrombosis Effects 0.000 description 4
230000001363 autoimmune Effects 0.000 description 4
230000001659 chemokinetic effect Effects 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
230000035558 fertility Effects 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
230000011132 hemopoiesis Effects 0.000 description 4
230000002439 hemostatic effect Effects 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000000099 in vitro assay Methods 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
230000007774 longterm Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000002751 oligonucleotide probe Substances 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000008929 regeneration Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
241000894007 species Species 0.000 description 4
230000008093 supporting effect Effects 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
230000029663 wound healing Effects 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
206010062016 Immunosuppression Diseases 0.000 description 3
102100026818 Inhibin beta E chain Human genes 0.000 description 3
102000014429 Insulin-like growth factor Human genes 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
108091008874 T cell receptors Proteins 0.000 description 3
230000005867 T cell response Effects 0.000 description 3
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
238000013019 agitation Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000002775 capsule Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
230000024245 cell differentiation Effects 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
230000001332 colony forming effect Effects 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
239000002537 cosmetic Substances 0.000 description 3
230000004940 costimulation Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000002372 labelling Methods 0.000 description 3
230000021633 leukocyte mediated immunity Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
210000000944 nerve tissue Anatomy 0.000 description 3
239000002245 particle Substances 0.000 description 3
208000027232 peripheral nervous system disease Diseases 0.000 description 3
208000033808 peripheral neuropathy Diseases 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000001603 reducing effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000004007 reversed phase HPLC Methods 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000008467 tissue growth Effects 0.000 description 3
230000000472 traumatic effect Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
206010007710 Cartilage injury Diseases 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
241000557626 Corvus corax Species 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
102000005720 Glutathione transferase Human genes 0.000 description 2
108010070675 Glutathione transferase Proteins 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
241001494479 Pecora Species 0.000 description 2
201000011152 Pemphigus Diseases 0.000 description 2
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
239000008156 Ringer's lactate solution Substances 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
241000282887 Suidae Species 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000002730 additional effect Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
230000007416 antiviral immune response Effects 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000008468 bone growth Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
230000021164 cell adhesion Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
230000035605 chemotaxis Effects 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000012411 cloning technique Methods 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
239000002131 composite material Substances 0.000 description 2
238000002316 cosmetic surgery Methods 0.000 description 2
230000000139 costimulatory effect Effects 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
238000004163 cytometry Methods 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
230000029087 digestion Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000001400 expression cloning Methods 0.000 description 2
238000001641 gel filtration chromatography Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
229910052588 hydroxylapatite Inorganic materials 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000008611 intercellular interaction Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000002642 intravenous therapy Methods 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000002609 medium Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
210000003061 neural cell Anatomy 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000011164 ossification Effects 0.000 description 2
230000002188 osteogenic effect Effects 0.000 description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000004626 polylactic acid Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000004952 protein activity Effects 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000011347 resin Substances 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
229910001415 sodium ion Inorganic materials 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000009772 tissue formation Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
229940078499 tricalcium phosphate Drugs 0.000 description 2
229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
235000019731 tricalcium phosphate Nutrition 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
LELMRLNNAOPAPI-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;aminophosphonous acid Chemical compound NP(O)O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LELMRLNNAOPAPI-UFLZEWODSA-N 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
IPZQNYYAYVRKKK-FXQIFTODSA-N Ala-Pro-Ala Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O IPZQNYYAYVRKKK-FXQIFTODSA-N 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
GMFAGHNRXPSSJS-SRVKXCTJSA-N Arg-Leu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GMFAGHNRXPSSJS-SRVKXCTJSA-N 0.000 description 1
SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 1
PIWWUBYJNONVTJ-ZLUOBGJFSA-N Asn-Asp-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N PIWWUBYJNONVTJ-ZLUOBGJFSA-N 0.000 description 1
QISZHYWZHJRDAO-CIUDSAMLSA-N Asn-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N QISZHYWZHJRDAO-CIUDSAMLSA-N 0.000 description 1
XTMZYFMTYJNABC-ZLUOBGJFSA-N Asn-Ser-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N XTMZYFMTYJNABC-ZLUOBGJFSA-N 0.000 description 1
DPWDPEVGACCWTC-SRVKXCTJSA-N Asn-Tyr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O DPWDPEVGACCWTC-SRVKXCTJSA-N 0.000 description 1
WSWYMRLTJVKRCE-ZLUOBGJFSA-N Asp-Ala-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O WSWYMRLTJVKRCE-ZLUOBGJFSA-N 0.000 description 1
208000034172 Autoimmune Experimental Myasthenia Gravis Diseases 0.000 description 1
208000030767 Autoimmune encephalitis Diseases 0.000 description 1
102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
108091028026 C-DNA Proteins 0.000 description 1
102000001902 CC Chemokines Human genes 0.000 description 1
108010040471 CC Chemokines Proteins 0.000 description 1
108050006947 CXC Chemokine Proteins 0.000 description 1
102000019388 CXC chemokine Human genes 0.000 description 1
101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
LRZPRGJXAZFXCR-DCAQKATOSA-N Cys-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N LRZPRGJXAZFXCR-DCAQKATOSA-N 0.000 description 1
QJUDRFBUWAGUSG-SRVKXCTJSA-N Cys-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N QJUDRFBUWAGUSG-SRVKXCTJSA-N 0.000 description 1
YZKOXEJTLWZOQL-GUBZILKMSA-N Cys-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CS)N YZKOXEJTLWZOQL-GUBZILKMSA-N 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000009024 Epidermal Growth Factor Human genes 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 description 1
NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 1
PXHABOCPJVTGEK-BQBZGAKWSA-N Glu-Gln-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O PXHABOCPJVTGEK-BQBZGAKWSA-N 0.000 description 1
YVYVMJNUENBOOL-KBIXCLLPSA-N Glu-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N YVYVMJNUENBOOL-KBIXCLLPSA-N 0.000 description 1
IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
CLODWIOAKCSBAN-BQBZGAKWSA-N Gly-Arg-Asp Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O CLODWIOAKCSBAN-BQBZGAKWSA-N 0.000 description 1
BGVYNAQWHSTTSP-BYULHYEWSA-N Gly-Asn-Ile Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BGVYNAQWHSTTSP-BYULHYEWSA-N 0.000 description 1
HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 1
FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
101001055216 Homo sapiens Interleukin-9 Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
UMYZBHKAVTXWIW-GMOBBJLQSA-N Ile-Asp-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UMYZBHKAVTXWIW-GMOBBJLQSA-N 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
108090000177 Interleukin-11 Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
108010002335 Interleukin-9 Proteins 0.000 description 1
102000000585 Interleukin-9 Human genes 0.000 description 1
241000235649 Kluyveromyces Species 0.000 description 1
241000222722 Leishmania <genus> Species 0.000 description 1
241000880493 Leptailurus serval Species 0.000 description 1
QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 description 1
CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 1
FOBUGKUBUJOWAD-IHPCNDPISA-N Leu-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FOBUGKUBUJOWAD-IHPCNDPISA-N 0.000 description 1
QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
BGGTYDNTOYRTTR-MEYUZBJRSA-N Leu-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(C)C)N)O BGGTYDNTOYRTTR-MEYUZBJRSA-N 0.000 description 1
206010065433 Ligament rupture Diseases 0.000 description 1
206010024774 Localised infection Diseases 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
FACUGMGEFUEBTI-SRVKXCTJSA-N Lys-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN FACUGMGEFUEBTI-SRVKXCTJSA-N 0.000 description 1
WTZUSCUIVPVCRH-SRVKXCTJSA-N Lys-Gln-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WTZUSCUIVPVCRH-SRVKXCTJSA-N 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
RRIHXWPHQSXHAQ-XUXIUFHCSA-N Met-Ile-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(O)=O RRIHXWPHQSXHAQ-XUXIUFHCSA-N 0.000 description 1
FZDOBWIKRQORAC-ULQDDVLXSA-N Met-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCSC)N FZDOBWIKRQORAC-ULQDDVLXSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
101001055215 Mus musculus Interleukin-9 Proteins 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
208000002565 Open Fractures Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101150012195 PREB gene Proteins 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
208000027086 Pemphigus foliaceus Diseases 0.000 description 1
208000010886 Peripheral nerve injury Diseases 0.000 description 1
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
208000013544 Platelet disease Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102400000745 Potential peptide Human genes 0.000 description 1
101800001357 Potential peptide Proteins 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 1
STASJMBVVHNWCG-IHRRRGAJSA-N Pro-His-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)NC(=O)[C@H]1[NH2+]CCC1)C1=CN=CN1 STASJMBVVHNWCG-IHRRRGAJSA-N 0.000 description 1
KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
108091005682 Receptor kinases Proteins 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
241000235347 Schizosaccharomyces pombe Species 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010053879 Sepsis syndrome Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
DLPXTCTVNDTYGJ-JBDRJPRFSA-N Ser-Ile-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(O)=O DLPXTCTVNDTYGJ-JBDRJPRFSA-N 0.000 description 1
ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
208000029033 Spinal Cord disease Diseases 0.000 description 1
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
102100036407 Thioredoxin Human genes 0.000 description 1
ILUOMMDDGREELW-OSUNSFLBSA-N Thr-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O ILUOMMDDGREELW-OSUNSFLBSA-N 0.000 description 1
102000036693 Thrombopoietin Human genes 0.000 description 1
108010041111 Thrombopoietin Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
108091061763 Triple-stranded DNA Proteins 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
VCAWFLIWYNMHQP-UKJIMTQDSA-N Val-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N VCAWFLIWYNMHQP-UKJIMTQDSA-N 0.000 description 1
LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 description 1
LJSZPMSUYKKKCP-UBHSHLNASA-N Val-Phe-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 LJSZPMSUYKKKCP-UBHSHLNASA-N 0.000 description 1
RYQUMYBMOJYYDK-NHCYSSNCSA-N Val-Pro-Glu Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RYQUMYBMOJYYDK-NHCYSSNCSA-N 0.000 description 1
206010054880 Vascular insufficiency Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
108010005233 alanylglutamic acid Proteins 0.000 description 1
108010047495 alanylglycine Proteins 0.000 description 1
108010087924 alanylproline Proteins 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229920013820 alkyl cellulose Polymers 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
150000004645 aluminates Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
235000005550 amino acid supplement Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
230000003172 anti-dna Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
108010013835 arginine glutamate Proteins 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000003462 bioceramic Substances 0.000 description 1
239000005312 bioglass Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000004903 cardiac system Anatomy 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
230000022159 cartilage development Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000004956 cell adhesive effect Effects 0.000 description 1
230000034196 cell chemotaxis Effects 0.000 description 1
230000017455 cell-cell adhesion Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000019771 cognition Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000012258 culturing Methods 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000009547 development abnormality Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
239000008355 dextrose injection Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
210000001840 diploid cell Anatomy 0.000 description 1
POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
210000000267 erythroid cell Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
210000003013 erythroid precursor cell Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
108010073628 glutamyl-valyl-phenylalanine Proteins 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000037308 hair color Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
102000052627 human IL9 Human genes 0.000 description 1
229940116886 human interleukin-6 Drugs 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000037189 immune system physiology Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000013546 insoluble monolayer Substances 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940028885 interleukin-4 Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
108010028930 invariant chain Proteins 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
108010053037 kyotorphin Proteins 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000010410 layer Substances 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
108010034529 leucyl-lysine Proteins 0.000 description 1
108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
210000004523 ligament cell Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000003526 lymphopoietic effect Effects 0.000 description 1
108010017391 lysylvaline Proteins 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000000693 micelle Substances 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
210000004296 naive t lymphocyte Anatomy 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000003170 nutritional factors Nutrition 0.000 description 1
230000000771 oncological effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
244000045947 parasite Species 0.000 description 1
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
201000001976 pemphigus vulgaris Diseases 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000003239 periodontal effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
108010073101 phenylalanylleucine Proteins 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000027317 positive regulation of immune response Effects 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
235000005974 protein supplement Nutrition 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002629 repopulating effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
210000003660 reticulum Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000037390 scarring Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000008354 sodium chloride injection Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000002536 stromal cell Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
231100000617 superantigen Toxicity 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
108060008226 thioredoxin Proteins 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000001875 tumorinhibitory effect Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000023577 vascular insufficiency disease Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA002276063A 1997-01-09 1998-01-09 Secreted proteins and polynucleotides encoding them Abandoned CA2276063A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US78089097A	1997-01-09	1997-01-09
US86451797A	1997-05-28	1997-05-28
US08/864,517		1997-05-28
US08/780,890		1998-01-08
PCT/US1998/000537 WO1998030584A2 (en)	1997-01-09	1998-01-09	Secreted proteins and polynucleotides encoding them

Publications (1)

Publication Number	Publication Date
CA2276063A1 true CA2276063A1 (en)	1998-07-16

Family

ID=27119772

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002276063A Abandoned CA2276063A1 (en)	1997-01-09	1998-01-09	Secreted proteins and polynucleotides encoding them

Country Status (5)

Country	Link
EP (1)	EP0970108A2 (de)
JP (1)	JP2001509153A (de)
AU (1)	AU5913898A (de)
CA (1)	CA2276063A1 (de)
WO (1)	WO1998030584A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999029860A1 (en) *	1997-12-08	1999-06-17	Ontogeny, Inc.	Cadherin-like polypeptides, methods and compositions related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5643781A (en) *	1992-12-29	1997-07-01	Doheny Eye Institute	DNA encoding protocadherin-42
US5798224A (en) *	1992-12-29	1998-08-25	Doheny Eye Institute	Nucleic acids encoding protocadherin

1998
- 1998-01-09 EP EP98902494A patent/EP0970108A2/de not_active Withdrawn
- 1998-01-09 AU AU59138/98A patent/AU5913898A/en not_active Abandoned
- 1998-01-09 JP JP53120298A patent/JP2001509153A/ja active Pending
- 1998-01-09 CA CA002276063A patent/CA2276063A1/en not_active Abandoned
- 1998-01-09 WO PCT/US1998/000537 patent/WO1998030584A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO1998030584A2 (en)	1998-07-16
EP0970108A2 (de)	2000-01-12
WO1998030584A3 (en)	1998-09-11
JP2001509153A (ja)	2001-07-10
AU5913898A (en)	1998-08-03

Legal Events

Date	Code	Title	Description
2004-01-09	FZDE	Dead

Publication	Publication Date	Title
US5723315A (en)	1998-03-03	Secreted proteins and polynucleotides encoding them
CA2269755A1 (en)	1998-04-30	Secreted proteins and polynucleotides encoding them
US5807709A (en)	1998-09-15	Secreted proteins and polynucleotides encoding them
EP1037899A1 (de)	2000-09-27	Sekretierte proteine und polynukleotide, die diese kodieren
EP1032593A1 (de)	2000-09-06	Ausgeschiedene proteine und dafür kodierende polynukleotide
WO1997048799A2 (en)	1997-12-24	Polynucleotides from human fetal brain encoding secreted proteins
CA2278770A1 (en)	1998-07-30	Secreted proteins and polynucleotides encoding them
US5958726A (en)	1999-09-28	Secreted proteins and polynucleotides encoding them
WO1997046682A2 (en)	1997-12-11	Polynucleotides from human adult pbmc encoding secreted proteins
WO1997046685A1 (en)	1997-12-11	Polynucleotides encoding secreted proteins from human dendritic cells
US20020106356A1 (en)	2002-08-08	Secreted proteins
EP0895539A2 (de)	1999-02-10	Sekretierte proteine und dafür kodierende polynukleotide
CA2273845A1 (en)	1998-06-11	Secreted proteins and polynucleotides encoding them
CA2276085A1 (en)	1998-07-16	Secreted proteins and polynucleotides encoding them
WO1998030584A2 (en)	1998-07-16	Secreted proteins and polynucleotides encoding them
CA2295212A1 (en)	1999-01-14	Secreted proteins and polynucleotides encoding them
CA2280968A1 (en)	1998-08-20	Secreted proteins and polynucleotides encoding them
EP0939805A2 (de)	1999-09-08	Sekretierte proteine und die dafür kodierende polynucleotide
CA2272050A1 (en)	1998-05-28	Secreted proteins and polynucleotides encoding them
WO1997048798A1 (en)	1997-12-24	Polynucleotide encoding secreted protein isolated from human dendritic cells
CA2291477A1 (en)	1998-11-26	Human semaphorin e and polynucleotides encoding it
WO1999032614A1 (en)	1999-07-01	Secreted proteins and polynucleotides encoding them
CA2257243A1 (en)	1997-12-11	Polynucleotides from human adult pbmc encoding secreted proteins
CA2267121A1 (en)	1998-04-09	Secreted proteins and polynucleotides encoding them
WO1998004695A1 (en)	1998-02-05	Secreted proteins and polynucleotides encoding them